Amin Yaqubie

874 total citations · 1 hit paper
15 papers, 578 citations indexed

About

Amin Yaqubie is a scholar working on Molecular Biology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Amin Yaqubie has authored 15 papers receiving a total of 578 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Surgery and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Amin Yaqubie's work include Hepatocellular Carcinoma Treatment and Prognosis (4 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (4 papers) and Melanoma and MAPK Pathways (3 papers). Amin Yaqubie is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (4 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (4 papers) and Melanoma and MAPK Pathways (3 papers). Amin Yaqubie collaborates with scholars based in United States, United Kingdom and Chile. Amin Yaqubie's co-authors include Nicole Kelly, Paul B. Chapman, Johannes G. Reiter, Yo Sup Moon, Evan J. Lipson, Benjamin Allen, Bert Vogelstein, Tibor Antal, Martin A. Nowak and Krishnendu Chatterjee and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and eLife.

In The Last Decade

Amin Yaqubie

15 papers receiving 572 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Evolutionary dynamics of cancer in response to targeted combination therapy

2013 433 citations Ivana Božić, Johannes G. Reiter et al. eLife profile →

Peers

Amin Yaqubie

ONCOL

PRM

Sharon Glaysher United Kingdom

Chirayu Patel United States

М. М. Цыганов Russia

Salo Ooft Netherlands

Megan Duggan United States

Neha Papneja Canada

Shaokun Shu China

Grace R. Anderson United States

Sofia Depner Germany

Davide Pellacani United Kingdom

Sharon Glaysher United Kingdom

Amin Yaqubie

324 ×1.1

286 ×1.4

ONCOL

112 ×0.6

143 ×1.1

PRM

10 ×0.1

Citations per year, relative to Amin Yaqubie Amin Yaqubie (= 1×) peers Sharon Glaysher

Countries citing papers authored by Amin Yaqubie

Since Specialization

Citations

This map shows the geographic impact of Amin Yaqubie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amin Yaqubie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amin Yaqubie more than expected).

Fields of papers citing papers by Amin Yaqubie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amin Yaqubie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amin Yaqubie. The network helps show where Amin Yaqubie may publish in the future.

Co-authorship network of co-authors of Amin Yaqubie

This figure shows the co-authorship network connecting the top 25 collaborators of Amin Yaqubie. A scholar is included among the top collaborators of Amin Yaqubie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amin Yaqubie. Amin Yaqubie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Mondaca, Sebastián, Henry Walch, Nikolaus Schultz, et al.. (2024). Clinical and Genomic Characterization of ERBB2 -Altered Gallbladder Cancer: Exploring Differences Between an American and a Chilean Cohort. JCO Global Oncology. 10(10). e2400090–e2400090. 1 indexed citations

Abou‐Alfa, Ghassan K., Tim Meyer, Richard Kinh Gian, et al.. (2024). Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without Mammalian Target of Rapamycin Inhibitors in Patients with Fibrolamellar Carcinoma. Liver Cancer. 14(1). 1–10. 1 indexed citations

Capanu, Marinela, Fergus Keane, Danny N. Khalil, et al.. (2023). P-266 Outcomes in advanced hepatocellular carcinoma (HCC) patients (pts) treated with immune checkpoint inhibitors (ICI). Annals of Oncology. 34. S109–S109. 1 indexed citations

O’Brien, Erin, et al.. (2023). Fertility post immune checkpoint blockade.. Journal of Clinical Oncology. 41(16_suppl). 12014–12014. 1 indexed citations

Zack, Travis, Jennifer Wild, Amin Yaqubie, et al.. (2023). Defining incidence and complications of fibrolamellar liver cancer through tiered computational analysis of clinical data. npj Precision Oncology. 7(1). 29–29. 5 indexed citations

Abou‐Alfa, Ghassan K., Kristen Bibeau, Nikolaus Schultz, et al.. (2022). Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma. Targeted Oncology. 17(5). 517–527. 22 indexed citations

Mondaca, Sebastián, Nikolaus Schultz, Juan Carlos Roa, et al.. (2022). Clinical and genomic characterization of ERBB2-altered gallbladder cancer.. Journal of Clinical Oncology. 40(16_suppl). 4114–4114. 3 indexed citations

Zou, Chenhui, Imane El Dika, Koen Vercauteren, et al.. (2021). Mouse characteristics that affect establishing xenografts from hepatocellular carcinoma patient biopsies in the United States. Cancer Medicine. 11(3). 602–617. 2 indexed citations

Harding, James J., Richard Kinh Gian, Amin Yaqubie, et al.. (2021). Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma. Cancer Medicine. 10(9). 3059–3067. 35 indexed citations

10.

Abou‐Alfa, Ghassan K., Tim Meyer, Jie Zhang, et al.. (2021). Evaluation of neratinib (N), pembrolizumab (P), everolimus (E), and nivolumab (V) in patients (pts) with fibrolamellar carcinoma (FLC).. Journal of Clinical Oncology. 39(3_suppl). 310–310. 5 indexed citations

11.

Dika, Imane H. El, Susan M. Geyer, Andrew B. Nixon, et al.. (2021). Alliance/CALGB 80802: Impact of hepatitis C (HCV) on doxorubicin (DO) + sorafenib (S) versus S in patients (pts) with advanced hepatocellular carcinoma (aHCC).. Journal of Clinical Oncology. 39(3_suppl). 325–325. 1 indexed citations

12.

Abou‐Alfa, Ghassan K., Kristen Bibeau, Nikolaus Schultz, et al.. (2021). Effect of FGFR2 alterations on survival in patients receiving systemic chemotherapy for intrahepatic cholangiocarcinoma.. Journal of Clinical Oncology. 39(3_suppl). 303–303. 14 indexed citations

13.

Harding, James J., Federica Catalanotti, Rodrigo Ramella Munhoz, et al.. (2015). A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases. The Oncologist. 20(7). 789–797. 50 indexed citations

14.

Božić, Ivana, Johannes G. Reiter, Benjamin Allen, et al.. (2013). Evolutionary dynamics of cancer in response to targeted combination therapy. eLife. 2. e00747–e00747. 433 indexed citations breakdown →

15.

Harding, James J., Federica Catalanotti, Amin Yaqubie, et al.. (2013). Vemurafenib (VEM) in patients (pts) with BRAF-mutant melanoma and brain metastases (mets).. Journal of Clinical Oncology. 31(15_suppl). 9060–9060. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact